Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 146 | 0.91 |
| pathways Reactome | 6 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 8281
Sealed predictions
- MAPK7 in dopamine neurons, braak-0.54 (p 0.133) → -0.27 (p 0.476)receipt 8288
Swarm cases
receipt 8288: MAPK7 in dopamine neurons, braak
- power
- full sample -0.44 (p 0.069, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.39 (p 0.111, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.54 (p 0.020, n 18). not the mix.
- skeptic
- leave-one-out range -0.61 to -0.37, sign flips 0; without severely affected donors -0.44 (p 0.069, n 18). robust.
- cell type
- strongest in microglia: -0.70 (p 0.0013, n 18) vs -0.44 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPK7 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAPK7 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.35 p 0.214 (needs p < 2.6e-4)
Receipts
loading the receipts